VerityRank
Recordati Industria Chimica e Farmaceutica S.p.A.
CompanyItaly

Recordati Industria Chimica e Farmaceutica S.p.A.

Recordati

Recordati Industria Chimica e Farmaceutica S.p.A. is an Italian biopharmaceutical company founded in 1926 and headquartered in Milan. It operates in specialty pharmaceuticals and rare disease therapeutics, with two reportable segments: Specialty & Primary Care (58.7% of FY2025 net revenue) and Rare Diseases (41.3%). The company employs 4,690 people as of December 31, 2025, and reported FY2025 revenue of USD 2.88 billion, net income of USD 488 million, total assets of EUR 5.252 billion, and shareholders' equity of EUR 1.92 billion. Recordati was listed on Euronext Milan under ticker REC until November 2026, when a consortium of CVC Capital Partners and Groupe Bruxelles Lambert, through acquisition vehicle Respighi BidCo S.p.A., completed a voluntary public tender offer at EUR 53.00 per share on November 9, 2026, reaching 91.9% ownership. This followed the tendering of a 46.82% stake held by Rossini S.a r.l. The company now faces a mandatory squeeze-out and delisting from Euronext Milan.

Strengths: Recordati's rare disease portfolio, contributing 41.3% of FY2025 revenue, includes orphan drugs such as Isturisa, Enjaymo, Signifor, Qarziba, Sylvant, Carbaglu, Panhematin, and Cystadrops, which command high barriers to entry and limited competition. The company operates eight manufacturing facilities globally, including two active pharmaceutical ingredient (API) chemical synthesis plants in Campoverde di Aprilia (Italy) and Cork (Ireland), and five formulation and packaging plants in Milan, Saint-Victor (France), Utebo (Spain), Cerkezkoy (Turkey), and Monastir (Tunisia), providing vertical integration and supply chain control. Commercial operations span approximately 150 countries, reaching more than 100 million Specialty & Primary Care patients and nearly 20,000 Rare Diseases patients annually, which supports scale in both segments. Recordati's established primary care brands, such as Zanidip, Zanipress, Seloken, Urorec, Eligard, Procto-Glyvenol, Lomexin, and Hexaspray, generate steady cash flows that fund rare disease expansion.

Weaknesses: The November 2026 tender offer at EUR 53.00 per share resulted in 91.9% ownership by Respighi BidCo, leaving only 2.28% in treasury shares and a small free float, which will lead to delisting and reduced public market scrutiny. This concentrated control by a financial consortium may prioritize debt servicing or exit timelines over long-term research investment. Recordati's revenue concentration in Europe is significant, with Italy, France, and Spain hosting major manufacturing and commercial operations, exposing the company to European pricing pressures and regulatory changes. The company faces competition from larger specialty pharmaceutical firms such as Ipsen, Chiesi Farmaceutici, Menarini, Almirall, Swedish Orphan Biovitrum (Sobi), Jazz Pharmaceuticals, and Hikma Pharmaceuticals, which may limit pricing power in both segments. Additionally, the rare disease segment's reliance on a limited number of orphan drugs, including Isturisa and Enjaymo, creates vulnerability to clinical setbacks or patent expirations.

Read More
ItalyFounded 192646908 manufacturing facilities… / 100
Listed onMILREC
Last updated: 2026-11-16 11:15 ET·By VerityRank Research Team·Methodology

Listed market data

REC.MI · MIL · weeklyHistory →
Market cap
$12 B
Share price
EUR 52.85
1Y change
+0.1%
Recent change
+0.4%

11-16

Since first close
×178

from 1995-03

Revenue (TTM)
$2.9 B
Revenue FY 2025 · updated 2026-11-16 11:15 ETSource ↗

Financial history

Full market history
EUR 0$0EUR 15$3.75 BEUR 30$7.5 BEUR 45$11.25 BEUR 60$15.0 B2025-122026-012026-022026-032026-042026-052026-062026-072026-082026-092026-102026-11
MonthCloseMarket capChange
  • 2026-11EUR 52.85$12 B-0.3%
  • 2026-10EUR 53.00$12 B+0.7%
  • 2026-09EUR 52.65$11.9 B+0.2%
  • 2026-08EUR 52.55$11.9 B+1.7%
  • 2026-07EUR 51.65$11.7 B+0.7%
  • 2026-06EUR 51.30$11.6 B-0.4%
  • 2026-05EUR 51.50$11.7 B+3.7%
  • 2026-04EUR 49.64$11.2 B+1.2%
  • 2026-03EUR 49.04$11.1 B+1.3%
  • 2026-02EUR 48.42$11 B+4.5%
  • 2026-01EUR 46.34$10.5 B-4.5%
  • 2025-12EUR 48.54$11 B—
Monthly closes · 2025-12 – 2026-11 · Full market history

Ownership & Control

Latest available filings
Controlling entity
Respighi BidCo S.p.A. (CVC Capital Partners & Groupe Bruxelles Lambert Consortium, incl. Rossini S.a r.l.) — 91.90%
Company type
Company
Insiders
46.82%
Institutions
35.15%(317 holders)
Free float
48.38%

Percentages are of total shares outstanding, aggregated from 13F-style filings via Yahoo Finance. Institutional figures reflect US-filed positions and may undercount owners filing elsewhere. No figure is shown where none is disclosed.

In the press

All coverage →4 latest headlines
Headlines aggregated from public feeds. Sentiment tags are keyword-based, not editorial judgement.

Recordati occupies a mid-cap niche in European specialty pharmaceuticals, with a rare disease franchise that differentiates it from generic-oriented peers. The November 2026 take-private by CVC Capital Partners and Groupe Bruxelles Lambert at EUR 53.00 per share removes public market discipline but also signals confidence in cash flow durability.

Industry Position

Recordati competes in a segment populated by larger specialists such as Ipsen, Chiesi Farmaceutici, Menarini, Almirall, Swedish Orphan Biovitrum (Sobi), Jazz Pharmaceuticals, and Hikma Pharmaceuticals. Its 41.3% revenue share from rare diseases places it among the more concentrated orphan drug players, but scale remains below that of Ipsen or Sobi. The company's 58.7% Specialty & Primary Care base provides ballast, with brands like Zanidip and Eligard sustaining cash generation across approximately 150 countries. In rare diseases, Recordati's portfolio of eight named orphan drugs, including Isturisa and Enjaymo, targets endocrinology and hemato-oncology, where competition is intense but patient populations are small and switching costs high. The 2026 tender offer at EUR 53.00 per share valued the equity at a premium that reflects these durable cash flows, yet the 91.9% ownership concentration limits the stock's liquidity and public benchmarking.

Competitive Advantages

Vertical integration through eight manufacturing facilities, including API synthesis in Campoverde di Aprilia and Cork, gives Recordati control over supply and cost in both segments. The rare disease portfolio's orphan drug designations confer market exclusivity periods that shield revenue from generic erosion, supporting the 41.3% segment contribution. Commercial reach across 150 countries, with more than 100 million Specialty & Primary Care patients and nearly 20,000 Rare Diseases patients annually, provides scale that smaller specialists lack. The primary care brands generate predictable cash flows that fund rare disease R&D and acquisitions, a model that has lifted revenue from USD 1.869 billion in FY2021 to USD 2.88 billion in FY2025.

Strategic Expansion

The CVC and GBL consortium's acquisition, completed on November 9, 2026, implies a strategy of operational streamlining and potential bolt-on acquisitions in rare diseases, funded by the company's EBITDA growth of 7.7% in the first nine months of 2026. Delisting from Euronext Milan will reduce reporting costs and allow longer-term investment horizons, but it also concentrates decision-making in a financial sponsor with a finite exit window. Expansion is likely to target additional orphan drug assets in metabolic and hemato-oncology disorders, leveraging the existing 150-country commercial infrastructure. The 2.28% treasury share holding (4,769,267 shares as of December 31, 2025) may be used for employee incentives or acquisition currency, though the mandatory squeeze-out will simplify the capital structure.

Risks & Outlook

The most material risk is revenue concentration in a small number of orphan drugs, where clinical failure or patent expiry could erode the 41.3% rare disease contribution. European pricing pressures, particularly in Italy, France, and Spain where Recordati has manufacturing and commercial hubs, could compress margins as governments seek pharmaceutical cost savings. The 91.9% control by a leveraged consortium raises the possibility of debt-funded dividends or asset sales that prioritize sponsor returns over long-term research. Competition from Ipsen, Sobi, and Jazz Pharmaceuticals in rare diseases, and from Hikma and Menarini in primary care, limits pricing power. On balance, Recordati's cash generation and niche portfolio support a stable outlook, but the loss of public listing and sponsor control warrant monitoring. VerityRank Score of 71/100.

Quick Facts

Headquarters

Milan, Lombardy, Italy

Founded

1926

Employees

4690

Market cap

$12 B

Factories

8 manufacturing facilities globally, including 2 active pharmaceutical ingredient (API) chemical synthesis plants in Campoverde di Aprilia (Italy) and Cork (Ireland), 5 pharmaceutical formulation and packaging plants in Milan (Italy), Saint-Victor (France), Utebo (Spain), Cerkezkoy (Turkey), and Monastir (Tunisia), and 1 dedicated orphan drug packaging and global distribution center in Nanterre (France).

Presence

Commercial operations across approximately 150 countries in EMEA, North America, Latin America, and APAC, reaching more than 100 million Specialty & Primary Care patients and nearly 20,000 Rare Diseases patients annually.

Listing

MIL: REC
Categories
Biopharmaceutical

Related

Data Sources & Methodology

This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.

VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.

Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.

Key references: Official Website